Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2015 |
| gptkbp:ATCCode |
V03AB38
|
| gptkbp:brand |
Praxbind
|
| gptkbp:CASNumber |
1333040-23-6
|
| gptkbp:developedBy |
gptkb:Boehringer_Ingelheim
|
| gptkbp:hasMolecularFormula |
C6468H9956N1714O2026S46
|
| https://www.w3.org/2000/01/rdf-schema#label |
idarucizumab
|
| gptkbp:indication |
emergency surgery in patients on dabigatran
life-threatening or uncontrolled bleeding in patients on dabigatran |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
binds to dabigatran and neutralizes its anticoagulant effect
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:pneumonia
fever delirium hypokalemia |
| gptkbp:target |
gptkb:dabigatran
|
| gptkbp:UNII |
Q1J8A4N6F2
|
| gptkbp:usedFor |
reversal of dabigatran anticoagulation
|
| gptkbp:bfsParent |
gptkb:DB12023
gptkb:dabigatran |
| gptkbp:bfsLayer |
6
|